Shares of Organogenesis (NASDAQ:ORGO - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $4.25, but opened at $4.40. Organogenesis shares last traded at $4.39, with a volume of 161,863 shares changing hands.
Organogenesis Price Performance
The company has a fifty day moving average of $3.54 and a 200 day moving average of $3.84. The firm has a market capitalization of $558.14 million, a P/E ratio of -25.88 and a beta of 1.70.
Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative net margin of 3.46% and a negative return on equity of 4.00%. The company had revenue of $86.69 million during the quarter, compared to the consensus estimate of $90.77 million. On average, sell-side analysts forecast that Organogenesis will post -0.07 EPS for the current year.
Insider Transactions at Organogenesis
In other news, insider Lori Freedman bought 142,379 shares of the stock in a transaction dated Thursday, June 5th. The shares were bought at an average cost of $2.91 per share, with a total value of $414,322.89. Following the completion of the transaction, the insider directly owned 837,437 shares of the company's stock, valued at $2,436,941.67. This trade represents a 20.48% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders purchased 252,264 shares of company stock valued at $725,732 over the last quarter. 33.00% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Organogenesis
A number of institutional investors have recently modified their holdings of ORGO. Wealth Enhancement Advisory Services LLC lifted its stake in Organogenesis by 10.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company's stock valued at $187,000 after acquiring an additional 4,239 shares in the last quarter. CWM LLC increased its holdings in Organogenesis by 8.9% in the 1st quarter. CWM LLC now owns 63,894 shares of the company's stock worth $276,000 after acquiring an additional 5,239 shares during the last quarter. Millennium Management LLC increased its holdings in Organogenesis by 2.8% in the 4th quarter. Millennium Management LLC now owns 208,420 shares of the company's stock worth $667,000 after acquiring an additional 5,765 shares during the last quarter. ProShare Advisors LLC grew its holdings in Organogenesis by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock valued at $65,000 after buying an additional 6,689 shares in the last quarter. Finally, American Century Companies Inc. grew its holdings in Organogenesis by 10.4% during the 4th quarter. American Century Companies Inc. now owns 98,892 shares of the company's stock valued at $316,000 after buying an additional 9,311 shares in the last quarter. 49.57% of the stock is owned by institutional investors and hedge funds.
Organogenesis Company Profile
(
Get Free Report)
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Featured Articles
Before you consider Organogenesis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.
While Organogenesis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
